跳至主要内容
临床试验/ACTRN12613000004763
ACTRN12613000004763已完成未知

The effect of thermal stimuli on the outcomes spontaneous pain, flare, allodynia and hyperalgesia in response to intradermal capsaicin in healthy male participants

Professor Paul Rolan0 个研究点目标入组 12 人开始时间: 2013年1月3日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 65 Years(—)
性别
Male

入选标准

  • A participant will be eligible for inclusion in this study only if all of the following criteria apply:
  • 2.Right handed
  • 3.Aged between 18-65 years inclusive
  • 4.In good general health without clinically significant renal, hepatic, cardiac or other disease, as determined by the Principal Investigator
  • 5.Agree to and be capable of signing the Informed Consent Form

排除标准

  • A participant will be excluded from the study if any of the following criteria apply:
  • 1.Significant scarring on the planned site of investigation
  • 2.Tattoos on the planned site of investigation
  • 3.Suffering from an active inflammatory process (e.g. acute pain, influenza, active infection, rheumatoid arthritis etc.)
  • 4.Have had a clinically significant infection in the 4 weeks prior to study day 1
  • 5.Suffering form an impaired immune response, e.g. HIV/AIDS sufferers, Hep B or C sufferers, organ transplant recipients or known current history of malignancy. Significance is to be determined by the investigator
  • 6.Taking immunosuppressant drugs e.g. azathioprine, methotrexate, cyclosporine
  • 7.Dark skin colouration that precludes flare assessment
  • 8.Positive urine drug screen for presence of non-prescribed drugs of abuse
  • 9.Positive breath alcohol concentration prior to study day 1 and 2
  • 10.Recent use of opioids (e.g. morphine use within 1 week, or codeine use (<30 mg) within last 5 days)
  • 11.Use of anxiolytics, anti-depressants and anti-epileptic medications within the previous 4 weeks
  • 12.Clinically significant abnormalities in blood tests conducted during screening, as determined by the Principal Investigator
  • 13.Sensory deficits at the planned quantitative sensory testing (QST) site resulting from medical conditions, such as diabetes; alcohol neuropathy; severe thyroid, liver or kidney diseases
  • 14.Suffering from a clinically diagnosed major psychiatric disorder, such as major depression; bipolar disorder; schizophrenia; anxiety disorder and psychosis
  • 15.History of excessive use of alcohol, defined as more than 28 units of alcohol per week
  • 16.Known disorder of thermal pain sensitivity (e.g. Raynaud’s Phenomenon)
  • 17.Inability to tolerate study procedures at screening familiarisation session
  • 18.Current or history of a chronic pain condition
  • 19.Frequent migraines, as determined by the Principal Investigator

研究者

发起方
Professor Paul Rolan

相似试验